GB8716904D0 - Stable pharmaceutical preparation - Google Patents

Stable pharmaceutical preparation

Info

Publication number
GB8716904D0
GB8716904D0 GB878716904A GB8716904A GB8716904D0 GB 8716904 D0 GB8716904 D0 GB 8716904D0 GB 878716904 A GB878716904 A GB 878716904A GB 8716904 A GB8716904 A GB 8716904A GB 8716904 D0 GB8716904 D0 GB 8716904D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical preparation
stable pharmaceutical
stable
preparation
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB878716904A
Other versions
GB2193631B (en
GB2193631A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of GB8716904D0 publication Critical patent/GB8716904D0/en
Publication of GB2193631A publication Critical patent/GB2193631A/en
Application granted granted Critical
Publication of GB2193631B publication Critical patent/GB2193631B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB8716904A 1986-07-18 1987-07-17 Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same Expired - Lifetime GB2193631B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948886 1986-07-18
JP16948986 1986-07-18
JP16948786 1986-07-18
JP16948686 1986-07-18

Publications (3)

Publication Number Publication Date
GB8716904D0 true GB8716904D0 (en) 1987-08-26
GB2193631A GB2193631A (en) 1988-02-17
GB2193631B GB2193631B (en) 1990-11-21

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8716904A Expired - Lifetime GB2193631B (en) 1986-07-18 1987-07-17 Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same

Country Status (24)

Country Link
KR (1) KR930004597B1 (en)
CN (1) CN1033738C (en)
AT (1) AT402259B (en)
AU (1) AU611856B2 (en)
BE (1) BE1000253A3 (en)
CA (1) CA1297007C (en)
CH (1) CH671157A5 (en)
DE (1) DE3723781C2 (en)
DK (1) DK171308B1 (en)
ES (1) ES2010226A6 (en)
FR (1) FR2601591B1 (en)
GB (1) GB2193631B (en)
GR (1) GR871067B (en)
HK (1) HK64893A (en)
HU (1) HU198627B (en)
IE (1) IE60290B1 (en)
IL (1) IL83220A (en)
IT (1) IT1218927B (en)
NL (1) NL192917C (en)
NO (1) NO171828C (en)
PT (1) PT85343B (en)
SE (1) SE503312C2 (en)
SG (1) SG64393G (en)
YU (1) YU47543B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (en) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Process for the preparation of an intravaginal pharmaceutical preparation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP3249147B2 (en) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2693907B1 (en) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa A method of administering granulocyte colony stimulating factor solutions.
EP0582932A1 (en) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutic system for the parenteral administration of hematopoietic growth factors
DE4242919A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Process for the preparation of storage-stable aqueous pharmaceutical preparations of G-CSF
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2000510813A (en) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Formulation for IL-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
AU749815B2 (en) * 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ATE389414T1 (en) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd STABLE PROTEIN SOLUTION BOTTLED IN A CONTAINER MADE OF HYDROPHOBIC RESIN AND A METHOD FOR STABILIZING THE SAME
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
CA2337661A1 (en) 2000-02-29 2001-08-29 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU8260701A (en) 2000-09-01 2002-03-13 Chugai Pharmaceutical Co Ltd Solution preparations stabilized over long time
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
WO2004020462A1 (en) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4 antagonist and use thereof
WO2004075913A1 (en) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
DE202006020194U1 (en) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF liquid formulation
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
CN107412737A (en) * 2010-01-19 2017-12-01 韩美科学株式会社 The liquid preparation of long-acting G CSF conjugates
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
KR20180063881A (en) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 Compositions and methods for the treatment of cancer
KR102033920B1 (en) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 How to treat acute myeloid leukemia
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
JP7549530B2 (en) * 2018-05-21 2024-09-11 中外製薬株式会社 Lyophilized preparation sealed in a glass container

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (en) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Stabilising protein during separation, purification and storage - by adding amphiphilic cpds., esp. lipid(s), ionic and or nonionic detergents
SE451844B (en) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd GLYCOPROTEIN, PROCEDURE FOR PREPARING THEREOF AND THERAPEUTIC AGENTS INCLUDING THE GLYCOPROTEIN
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS61227526A (en) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
JPS6191131A (en) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd Method and composition for preventing adsorption of pharmaceutical
WO1986004587A1 (en) * 1985-02-05 1986-08-14 Cetus Corporation Purification of native colony stimulating factor-1
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (en) * 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment

Also Published As

Publication number Publication date
CH671157A5 (en) 1989-08-15
DE3723781C2 (en) 1999-09-02
HU198627B (en) 1989-11-28
AU7566587A (en) 1988-01-21
ES2010226A6 (en) 1989-11-01
HK64893A (en) 1993-07-16
IL83220A (en) 1993-01-31
IT8767594A0 (en) 1987-07-10
SE503312C2 (en) 1996-05-13
CA1297007C (en) 1992-03-10
GB2193631B (en) 1990-11-21
BE1000253A3 (en) 1988-09-27
KR880001297A (en) 1988-04-22
NO171828C (en) 1993-05-12
IL83220A0 (en) 1987-12-31
AT402259B (en) 1997-03-25
KR930004597B1 (en) 1993-06-01
SE8702907L (en) 1988-01-19
IE871933L (en) 1988-01-18
HUT44941A (en) 1988-05-30
CN1033738C (en) 1997-01-08
AU611856B2 (en) 1991-06-27
DE3723781A1 (en) 1988-01-21
PT85343B (en) 1990-04-30
NO872966L (en) 1988-01-19
DK171308B1 (en) 1996-09-02
SG64393G (en) 1993-08-06
DK368387A (en) 1988-01-19
FR2601591A1 (en) 1988-01-22
GB2193631A (en) 1988-02-17
IE60290B1 (en) 1994-06-29
FR2601591B1 (en) 1991-04-26
DK368387D0 (en) 1987-07-15
YU47543B (en) 1995-10-03
PT85343A (en) 1987-08-01
NL192917B (en) 1998-01-05
NO171828B (en) 1993-02-01
GR871067B (en) 1987-11-19
NO872966D0 (en) 1987-07-16
IT1218927B (en) 1990-04-24
YU134287A (en) 1989-06-30
NL8701640A (en) 1988-02-16
SE8702907D0 (en) 1987-07-17
CN87104963A (en) 1988-02-24
NL192917C (en) 1998-05-07
ATA177587A (en) 1996-08-15

Similar Documents

Publication Publication Date Title
GB8716904D0 (en) Stable pharmaceutical preparation
GB8610572D0 (en) Pharmaceutical preparation
GR862727B (en) Pharmaceutical preparation
GB2194144B (en) Stable pharmaceutical gel preparation
GB8607570D0 (en) Vaginal pharmaceutical preparation
ZA875631B (en) Pharmaceutical formulations
CS8700282A2 (en) Nicorandil-containing stable pharmaceutical
GB8607817D0 (en) Drug preparation
GB2187953B (en) Pharmaceutical formulation
ZA8667B (en) Pharmaceutical preparation
ZA877699B (en) Pharmaceutical combination
GB8721313D0 (en) Pharmaceutical preparation
ZA899948B (en) Pharmaceutical preparation
ZA876048B (en) Pharmaceutical formulation
GR871915B (en) Pharmaceutical formulations
ZA875281B (en) Zylometzoline-containing pharmaceutical preparations
EG18240A (en) New pharmaceutical preparation
ZA876959B (en) Pharmaceutical formulations
GB8603097D0 (en) Pharmaceutical formulations
HRP920590B1 (en) New pharmaceutical preparation
BG43026A1 (en) Lyposomic pharmaceutical form
EG18297A (en) New drug preparation
GB8630904D0 (en) Pharmaceutical formulation
GB8630769D0 (en) Pharmaceutical formulation
GB8630767D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20070716